Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TRK-820

Phase 1Small molecule

TToray Industries, Inc

1

Indications

1

Total Trials

0

Active Trials

0

Competitors

Clinical

Trials by Indication[1]

Pruritus1 trial

TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus

Completed·TToray Industries, Inc·Phase 1·NCT03002233·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TRK-820. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TRK-820 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TRK-820. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Toray Industries, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TToray Industries, Inc

Related News